Gedeon Richter Strikes $16.5m Global Tocilizumab Deal

Agreement For Biosimilar To Actemra/RoActemra Reached With Taiwan’s Mycenax

 
• By Dave Wallace

Gedeon Richter has struck a deal worth $16.5m with Taiwan’s Mycenax for global rights to a tocilizumab biosimilar version of Actemra/RoActemra, setting a date for planned launches in the EU, Japan, Canada and Australia.

Tocilizumab_Injections
The deal provides Richter with a rival to Actemra/RoActemra • Source: Shutterstock

More from Deals

More from Business